Bristol-Meyers Squibb’s Opdivo (nivolumab) has just been approved by the FDA for patients with a microsatellite instability-high tumors (also known as MSI-H) or mismatched repair deficiency (dMMR). The approval was specifically for patients whose cancer has progressed following Fluoropyrimidine, Oxaliplatin, and Irinotecan.
Opdivo joins Merck’s Keytruda (pembrolizumab) as the second immunotherapy drug to be approved within four months. Here’s what you need to know.
No comments:
Post a Comment